Merck’s $1.35 billion purchase is the latest deal driven by patent cliff fears
Imago BioSciences buyout is intended to diversify the company’s revenue streams
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.
Subscribe now